Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1561-1574

  Martin, Valentina ^a,b   Corso, Simona ^a,b   Comoglio, Paolo M ^a,b   Giordano, Silvia ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Drug dependence; MET; MV DN30 monovalent antibody; Resistance; TKIs

Indexed keywords

MONOCLONAL ANTIBODY; MV DN30 MONOCLONAL ANTIBODY; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; EMBRYO; ENZYMATIC DEGRADATION; ENZYME INHIBITION; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC50; LUNG CANCER CELL LINE; PHARMACOGENETICS; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TURNOVER TIME; WESTERN BLOTTING;

EID: 84911975314     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.06.010     Document Type: Article

References (60)

1. Arora A., Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J.Pharmacol. Exp. Ther. 2005, 315:971-979.
2. Bardelli A., Corso S., Bertotti A., Hobor S., Valtorta E., Siravegna G., Sartore-Bianchi A., Scala E., Cassingena A., Zecchin D., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013, 3:658-673.
3. Bardelli A., Jänne P.A. The road to resistance: EGFR mutation and cetuximab. Nat. Med. 2012, 18:199-200.
4. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006, 312:1175-1178.
5. Baselga J., Cortés J., Kim S.B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., Pienkowski T., Knott A., Clark E., Benyunes M.C., Ross G., Swain S.M. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N.Engl. J. Med. 2012, 366:109-119. CLEOPATRA Study Group.
6. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., Balak M., Chang W.C., Yu C.J., Gazdar A., Pass H., Rusch V., Gerald W., Huang S.F., Yang P.,C., Miller V., Ladanyi M., Yang C.H., Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U S A 2007, 104:20932-20937.
7. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4:915-925.
8. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F., Aaronson S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251:802-804.
9. Capelan M., Pugliano L., De Azambuja E., Bozovic I., Saini K.S., Sotiriou C., Loi S., Piccart-Gebhart M.J. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann. Oncol. 2013, 24:273-282.
10. Cepero V., Sierra J.R., Corso S., Ghiso E., Casorzo L., Perera T., Comoglio P.M., Giordano S. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 2010, 70:7580-7590.
11. Cepero V., Sierra J.R., Giordano S. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. Curr. Pharm. Des. 2010, 16:1396-1409.
12. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
13. Comoglio P.M., Trusolino L. Invasive growth: from development to metastasis. J.Clin. Invest. 2002, 109:857-862.
14. Corso S., Ghiso E., Cepero V., Sierra J.R., Migliore C., Bertotti A., Trusolino L., Comoglio P.M., Giordano S. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol. Cancer 2010, 9:121.
15. Corso S., Giordano S. Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective. Cancer Discov. 2013, 3:978-992.
16. Corso S., Migliore C., Ghiso E., De Rosa G., Comoglio P.M., Giordano S. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 2008, 27:684-693.
17. Das Thakur M., Salangsang F., Landman A.S., Sellers W.R., Pryer N.K., Levesque M.P., Dummer R., McMahon M., Stuart D.D. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494:251-255.
18. Di Renzo M.F., Olivero M., Giacomini A., Porte H., Chastre E., Mirossay L., Nordlinger B., Bretti S., Bottardi S., Giordano S. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1995, 1:147-154.
19. Engelman J.A., Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 2008, 18:73-79.
20. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Jänne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
21. Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M., Rogers A., Lifshits E., Brown A., Lee C., Christensen J.G., Kwiatkowski D.J., Engelman J.A., Jänne P.A. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010, 29:2346-2356.
22. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
23. Follenzi A., Ailles L.E., Bakovic S., Geuna M., Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 2000, 25:217-222.
24. Foveau B., Ancot F., Leroy C., Petrelli A., Reiss K., Vingtdeux V., Giordano S., Fafeur V., Tulasne D. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol. Biol. Cell 2009, 20:2495-2507.
25. Funakoshi Y., Mukohara T., Tomioka H., Ekyalongo R.C., Kataoka Y., Inui Y., Kawamori Y., Toyoda M., Kiyota N., Fujiwara Y., Minami H. Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Invest. New Drugs 2013, 31:1158-1168.
26. Gambarotta G., Boccaccio C., Giordano S., Ando M., Stella M.C., Comoglio P.M. Ets up-regulates MET transcription. Oncogene 1996, 13:1911-1917.
27. Giordano S., Di Renzo M.F., Ferracini R., Chiadò-Piat L., Comoglio P.M. p145, a protein with associated tyrosine kinase activity in a human gastric carcinoma cell line. Mol. Cell Biol. 1988, 8:3510-3517.
28. Giordano S., Ponzetto C., Di Renzo M.F., Cooper C.S., Comoglio P.M. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 1989, 339:155-156.
29. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 2004, 4:361-370.
30. Hwang C.I., Matoso A., Corney D.C., Flesken-Nikitin A., Körner S., Wang W., Boccaccio C., Thorgeirsson S.S., Comoglio P.M., Hermeking H., Nikitin A.Y. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc. Natl. Acad. Sci. U S A 2011, 108:14240-14245.
31. Ivan M., Bond J.A., Prat M., Comoglio P.M., Wynford-Thomas D. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997, 14:2417-2423.
32. Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbison C.T., Wu S., Wong T.W., Huang X., Takimoto C.H., Godwin A.K., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J.Clin. Oncol. 2007, 25:3230-3237.
33. Lennerz J.K., Kwak E.L., Ackerman A., Michael M., Fox S.B., Bergethon K., Lauwers G.Y., Christensen J.G., Wilner K.D., Haber D.A., Salgia R., Bang Y.J., Clark J.W., Solomon B.J., Iafrate A.J. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J.Clin. Oncol. 2011, 29:4803-4810.
34. Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu. Rev. Pharmacol. Toxicol. 2013, 53:161-185.
35. Lutterbach B., Zeng Q., Davis L.J., Hatch H., Hang G., Kohl N.E., Gibbs J.B., Pan B.S. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007, 67:2081-2088.
36. Migliore C., Martin V., Leoni V.P., Restivo A., Atzori L., Petrelli A., Isella C., Zorcolo L., Sarotto I., Casula G., et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin. Cancer Res. 2012, 18:737-747.
37. Montagut C., Dalmases A., Bellosillo B., Crespo M., Pairet S., Iglesias M., Salido M., Gallen M., Marsters S., Tsai S.P., Minoche A., Seshagiri S., Somasekar S., Serrano S., Himmelbauer H., Bellmunt J., Rovira A., Settleman J., Bosch F., Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 2012, 18:221-223.
38. Naldini L., Vigna E., Narsimhan R.P., Gaudino G., Zarnegar R., Michalopoulos G.K., Comoglio P.M. Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991, 6:501-504.
39. Pacchiana G., Chiriaco C., Stella M.C., Petronzelli F., De Santis R., Galluzzo M., Carminati P., Comoglio P.M., Michieli P., Vigna E. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J.Biol. Chem. 2010, 285:36149-36157.
40. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
41. Perera T. Selective Inhibition of Met Kinase: JNJ38877605 2007, Spring CTEP Early Drug Development Meeting. Rockville, MD, USA.
42. Perera T., Lavrijssen T., Janssens B., Geerts T., King P., Mevellec L., Cummings M., Lu T., Johnson D., Page M. JNJ38877605: a Selective Met Kinase Inhibitor Inducing Regression of Met Driven Tumor Models 2008, Presented at the 99th AACR Annual Meeting; 2008, April 12-16, San Diego, CA, USA: Abstract #4837.
43. Peters S., Adjei A.A. MET: a promising anticancer therapeutic target. Nat. Rev. Clin. Oncol. 2012, 9:314-326.
44. Petrelli A., Circosta P., Granziero L., Mazzone M., Pisacane A., Fenoglio S., Comoglio P.M., Giordano S. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl. Acad. Sci. U S A 2006, 103:5090-5095.
45. Prat M., Crepaldi T., Gandino L., Giordano S., Longati P., Comoglio P.M. C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol. Cell Biol. 1991, 11:5954-5962.
46. Prat M., Crepaldi T., Pennacchietti S., Bussolino F., Comoglio P.M. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J.Cell Sci. 1998, 111(Pt 2):237-247.
47. Qi J., McTigue M.A., Rogers A., Lifshits E., Christensen J.G., Jänne P.A., Engelman J.A. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011, 71:1081-1091.
48. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J.Clin. Oncol. 2004, 22:1201-1208.
49. Schmidt L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 1997, 16:68-73.
50. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12:278-287.
51. Shattuck D.L., Miller J.K., Carraway K.L., Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008, 68:1471-1477.
52. Sierra J.R., Cepero V., Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 2010, 9:75.
53. Smolen G.A., Sordella R., Muir B., Mohapatra G., Barmettler A., Archibald H., Kim W.J., Okimoto R.A., Bell D.W., Sgroi D.C., Christensen J.G., Settleman J., Haber D.A. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U S A 2006, 103:2316-2321.
54. Spigel D.R., Ervin T., Ramlau R., Daniel D., Goldschmidt J., Krzakowski M., Godbert B., Yu W., Patel P.H., Peterson A. Randomized multicenter double-blind placebo-controlled phase II study evaluating MetmAb, an antibody to Met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2010, 1(Suppl. 8). viii7.
55. Spigel D.R., Edelman M.J., Mok T., O'Byrne K., Paz-Ares L., Yu W., Rittweger K., Thurm H. Treatment rationale study design for the MetLung trial: a randomized, double-blind phase III study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV met-positive non-small-cell lung cancer. Clin. Lung Cancer 2012, 13:500-504. MetLung Phase III Study Group.
56. Trusolino L., Bertotti A. Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation. Cancer Discov. 2012, 2:876-880.
57. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 2007, 18:977-984.
58. Vigna E., Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J.Gene Med. 2000, 2:308-316.
59. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
60. Weinstein I.B., Joe A.K. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 2006, 3:448-457.